TrialPediatric dermatology2025

Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 Years.

Adelaide A Hebert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.